SFOR could reduce O/S perhaps by 1billion shares
Kay has
SFOR could reduce O/S perhaps by 1billion shares
Kay has said he would be inclined to buy shares back. He didn't say by how many. could 500 mil to a Billion shares, SFOR management would benefit in a huge way (wont hurt us either lol) in positioning itself for a possible buy out in time. The PPS would soar in the 50 to 100 range with less shares and lower float.
SFOR stands to get 100's millions in damages and 10's of millions in monthly revenues from law suits and 10's of millions of sales from sales from their channel partner ACS from Government and Payment card industry and other sales.
It would take 20 million to buy back 1 billion shares at .02
The long anticipated sales must be flowing in to the degree to uplist.
But the share buy back will benefit all investor and company alike. IMO
2
Zerify Inc (ZRFY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...
Continue Reading
Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...
Continue Reading
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...
Continue Reading
HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...
Continue Reading
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....
Continue Reading
What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...
Continue Reading
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding the Class Action Lawsuit Against Joint Stock Company Kaspi.kz Levi & Korsinsky, LLP has brought to light an important class action lawsuit concerning the Joint Stock Company Kaspi.kz (NASDAQ: KSPI). This initiative aims to provide legal recourse to investors who may have suffered due to alleged fraudulent activities that negatively impacted the company's...
Continue Reading
Verdafero Launches New Emissions Reporting Service Verdafero, a prominent player in sustainability solutions, has introduced an expanded service for emissions reporting that now includes comprehensive tracking and analysis of Scope 1, Scope 2, and Scope 3 emissions specifically for the hospitality industry. This innovative offering provides businesses in this sector with...
Continue Reading
Key Analyst Ratings for Prominent Stocks Wall Street analysts have recently begun covering some noteworthy companies, aiming to provide insights for potential investors. Analyst ratings can spark interest in stocks and guide buying decisions, especially when backed by thorough research. This article highlights the initiation of coverage on five significant stocks,...
Continue Reading
Repertoire Immune Medicines and Eli Lilly Announce Collaboration Repertoire Immune Medicines is excited to announce a significant strategic collaboration with Eli Lilly and Company, focusing on the development of tolerizing therapies to treat various autoimmune diseases. This partnership is set to leverage Repertoire's advanced DECODE™ platform, designed to pioneer T...
Continue Reading
Manhattan Associates Faces Lawsuit Amid Significant Losses A class action lawsuit has emerged against Manhattan Associates, Inc. (NASDAQ: MANH), a prominent player in software solutions for supply chain management and inventory operations. This legal action highlights concerns from investors who have experienced notable financial losses stemming from alleged...
Continue Reading